Technical Analysis for NPPNY - Nippon Paper Group Inc Unsponsored ADR

Grade Last Price % Change Price Change
grade B 19.85 -0.65% -0.1300
NPPNY closed down 0.65 percent on Thursday, August 13, 2020, on 74 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical NPPNY trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -0.65%
Stochastic Reached Overbought Strength -0.65%
Wide Bands Range Expansion -0.65%
Gapped Up Strength -0.65%
Overbought Stochastic Strength -0.65%
Stochastic Sell Signal Bearish 0.46%
Narrow Range Bar Range Contraction 0.46%
Older signals for NPPNY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. Its products comprise Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company's products also include Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; Regtect for maintaining alcohol abstinence; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Baynas for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; and Onetram and Tramal for cancer and chronic pain. In addition, it researches and develops, and markets drugs in the areas of urology, gynecology, otorhinolaryngology, and orthopedics. In addition, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Medicine Medical Specialties Cancer Pharmaceuticals Clinical Medicine Diseases Inflammation Prostate Cancer Chronic Pain Antineoplastic Drugs Allergies Erectile Dysfunction Leukemia Allergology Allergic Rhinitis Conjunctivitis Gastrointestinal Disorders Pulmonary Arterial Hypertension Rhinitis Solid Tumor Urological Diseases Acute Leukemia Hematologic Malignancies Myelodysplastic Syndrome Vertigo

Is NPPNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 22.84
52 Week Low 12.4
Average Volume 1,355
200-Day Moving Average 16.9750
50-Day Moving Average 19.4883
20-Day Moving Average 18.9498
10-Day Moving Average 19.8507
Average True Range 0.8213
ADX 11.88
+DI 51.8490
-DI 46.0105
Chandelier Exit (Long, 3 ATRs ) 19.0561
Chandelier Exit (Short, 3 ATRs ) 17.6639
Upper Bollinger Band 21.8136
Lower Bollinger Band 16.0860
Percent B (%b) 0.66
BandWidth 30.2251
MACD Line 0.3604
MACD Signal Line 0.2158
MACD Histogram 0.1447
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.8500
Resistance 3 (R3) 19.8500 19.8500 19.8500
Resistance 2 (R2) 19.8500 19.8500 19.8500 19.8500
Resistance 1 (R1) 19.8500 19.8500 19.8500 19.8500 19.8500
Pivot Point 19.8500 19.8500 19.8500 19.8500 19.8500
Support 1 (S1) 19.8500 19.8500 19.8500 19.8500 19.8500
Support 2 (S2) 19.8500 19.8500 19.8500 19.8500
Support 3 (S3) 19.8500 19.8500 19.8500
Support 4 (S4) 19.8500